Latest News

Merck's 21-Valent Pneumococcal Vaccine Shows Positive Immune Response in At-Risk Children, Adolescents
Merck's 21-Valent Pneumococcal Vaccine Shows Positive Immune Response in At-Risk Children, Adolescents

September 11th 2025

Merck's CAPVAXIVE could cover approximately 78% of invasive pneumococcal disease cases in youth with chronic health conditions, vs other approved pneumococcal conjugate vaccines.

Phase 3 Data Confirm Strong Immune Response With Pfizer-BioNTech LP.8.1 COVID-19 Vaccine for 2025–2026 Season / image credit: ©diy13/AdobeStock
Phase 3 Data Confirm Strong Immune Response With Pfizer-BioNTech LP.8.1 COVID-19 Vaccine for 2025–2026 Season

September 9th 2025

 High-Dose Influenza Vaccine Reduces Risk of Myocarditis and Pericarditis in Older Adults / Image credit: University of Copenhagen
High-Dose Influenza Vaccine Reduces Risk of Myocarditis and Pericarditis in Older Adults

September 5th 2025

Data Show Many US Adults Lack Awareness About HPV, Vaccine: Daily Dose / image credit: ©New Africa/AdobeStock
Data Show Many US Adults Lack Awareness About HPV, Vaccine: Daily Dose

September 5th 2025

Data Shows Initial RSV Vaccine Uptake is Low Among Older Adults: Daily Dose / image credit: ©New Africa/AdobeStock
Data Shows Initial RSV Vaccine Uptake is Low Among Older Adults: Daily Dose

September 3rd 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.